Microneedles-Mediated Transdermal Delivery

Authors: M. Petchsangsai, N. Wonglertnirant, T. Rojanarata, P. Opanasopit, T. Ngawhirunpat

Abstract:

The objective of the present study was to evaluate the potential of hollow microneedles for enhancing the transdermal delivery of Bovine Serum Albumin (MW~66,000 Da)-Fluorescein Isothiocyanate (BSA-FITC) conjugate, a hydrophilic large molecular compound. Moreover, the effect of different formulations was evaluated. The series of binary mixtures composed of propylene glycol (PG) and pH 7.4 phosphate buffer solution (PBS) was prepared and used as a medium for BSA-FITC. The results showed that there was no permeation of BSA-FITC solution across the neonatal porcine skin without using hollow microneedles, whereas the cumulative amount of BSA-FITC released at 8 h through the neonatal porcine skin was about 60-70% when using hollow microneedles. Furthermore, the results demonstrated that the higher volume of PG in binary mixtures injected, the lower cumulative amount of BSA-FITC released and release rate of BSA-FITC from skin. These release profiles of BSA-FITC in binary mixtures were expressed by Fick-s law of diffusion. These results suggest the utilization of hollow microneedle to enhance transdermal delivery of protein and provide useful information for designing an effective hollow microneedle system.

Keywords: Hydrophilic macromolecules, Microneedles, Propylene glycol, Transdermal drug delivery

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1060044

References:

[1] J. Hadgraft, "Skin, the final frontier," Int J Pharm, vol. 224, 2001, pp. 1-18.
[2] A. Naik, K.N. Yogeshvar, and G.H. Richard, "Transdermal drug delivery: Overcoming the skin-s barrier function," PSTT, vol. 3, 2000, 318-326.
[3] S.N. Murthy, and H.N. Shivakumar, "Topical and transdermal drug delivery," in Handbook of non-invasive drug delivery systems, 2010, pp. 1-36.
[4] M. Milewski, and A. L. Stinchcomb, "Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride," Pharm Res, vol. 28, 2010, pp. 124-134.
[5] H. A. E. Benson, "Transdermal drug delivery: Penetration enhancement techniques," Current Drug Delivery, vol. 2, 2005, pp. 23-33.
[6] S. Henry, M.V. Devin, A.G. Mark, and P.R. Mark, "Microfabricated microneedles: A novel approach to transdermal drug delivery," J. Pharm. Sci., vol. 87, 1998, pp. 922-925.
[7] P.R. Mark, "Microneedles for transdermal drug delivery," Adv. Drug Del. Rev., vol 56, 2004, pp. 581-587.
[8] B. Bendas, S. Ulrike, and N. Reinhard, "Influence of propylene glycol as cosolvent on mechanisms of drug transport from hydrogels," Int. J. Pharm., vol. 116, 1995, pp. 19-30.
[9] P. Karade, and S. Mitragotri, "Enhancement of transdermal drug delivery via synergistic action of chemicals," Biochim. Biophys. Acta., vol 1788, 2009, pp. 2362-2373.
[10] W. Nanthida, H. Todo, O. Preneet, N. Tanasait, and K. Sugibayashi, "Macromolecular delivery into skin using a hollow microneedle," Biol. Pharm. Bull., vol. 33, 2010, pp. 1988-1993.
[11] P. Maleenart, W. Nanthida, R. Theerasak, O. Preneet, and N. Tanasait, "Application of hollow microneedle for transdermal delivery of bovine serum albumin-florescein isothiocyanate conjugate," Adv. Mat. Res., vol. 338, 2011, pp. 365-368.
[12] D.F. Ryan et al., "Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution," J. Control. Release., vol. 147, 2010, pp. 333-341.
[13] W.Q. Lin et al., "Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux®) technology," Pharm. Res., vol. 18, 2001, pp. 1789-1793.
[14] D.V. McAllister et al., "Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies," PNAS, vol. 100, 2003, pp. 13755-13760.
[15] G.S. Harvinder, and P.R. Mark, "Coated microneedles for transdermal delivery," J. Control. Release., vol. 117, 2007, pp. 227-237.